These mutations alter IDH enzyme activity, leading to the production of an abnormal metabolite, 2-hydroxyglutarate (2-HG), which accumulates in cells and affects multiple epigenetic regulatory mechanisms, including changes in DNA and histone methylation, thereby driving tumor formation and progression. Here, IDH2 is linked to neoplasm.